|
||
Original Article |
patricia_detmers{at}merck.com
| Abstract |
|---|
|
|
|---|
Key Words: enhanced green fluorescent protein U373 cells intracellular trafficking
Cells that express plasma membrane–bound (m)CD14,1 either naturally or through transfection, bind bacterial LPS. Monomeric LPS is removed from LPS aggregates and reaches mCD14 by a two-step process in serum 1. The serum protein LPS binding protein (LBP) binds to LPS aggregates and transfers monomers to a soluble (s) form of CD14, also present in serum. sCD14, in turn, may transfer LPS either to serum lipoprotein particles, causing LPS neutralization, or to cells, leading to production of cytokines and other responses. Transfer of LPS between CD14 molecules is a rapid process 2, suggesting that the movement of LPS from sCD14 to mCD14 on mCD14-bearing cells is likely to be more rapid than the movement of LPS from sCD14 to the surfaces of cells that do not express CD14.
The importance of mCD14 to the binding of LPS and the cellular responses that follow is underscored by a variety of observations. Blockade of LPS binding to mCD14 on leukocytes with mAbs 3 abrogates responses such as cytokine production by monocytes 4 and enhanced integrin-dependent adhesion by neutrophils 25. In addition, paroxysmal nocturnal hemoglobinuria, a disease characterized by a variable deficiency in the expression of mCD14 and other glycosylphosphatidyl inositol (GPI)-linked proteins on hemopoietic cells, renders monocytes less sensitive to LPS 678. Perhaps the strongest evidence for the primacy of mCD14 in mediating responses to LPS is the observation that monocytes from CD14-deficient mice show a strongly attenuated cytokine response to LPS 9. Moreover, transfection with mCD14 endows various cell types that do not otherwise express CD14 with the ability either to become responsive to LPS 10 or to become sensitive to much lower concentrations of LPS 1112. Thus, mCD14 serves as the initial site of interaction between LPS and the surfaces of CD14-bearing cells.
Several lines of evidence suggest that after binding to mCD14, LPS must be internalized to initiate intracellular signaling leading to cellular responses. Recently, we and others have observed that fluorescently labeled LPS is rapidly endocytosed when it is presented to neutrophils or cultured human monocytes as monomeric LPS complexed with sCD14 1314. In neutrophils, integrin-mediated adhesion in response to LPS exhibits a lag of 10–20 min and is completely blocked by phosphatidyl inositol 3 kinase inhibitors or by lowering the temperature to 19°C, two treatments that prevent vesicular transport 13. Thieblemont and Wright demonstrated that macrophages from mice with the LPS-hyporesponsive (Lpsd) trait are defective in vesicular transport of LPS 14. Furthermore, LPS antagonists block both the transport of LPS inside the cell 15 and cellular responses to LPS. Internalization of LPS may therefore be a key process for eliciting responses from cells expressing mCD14.
Although LPS internalization has been directly observed under a variety of circumstances, the precise role of mCD14 in this process is not known. The ability of CD14 to transfer LPS to high density lipoprotein particles 16 and phospholipid micelles 17 suggests that mCD14 might participate in the catalytic transfer of LPS to the lipid bilayer of the plasma membrane. LPS may then move within the cell independently of mCD14 or in a vesicle also containing mCD14. Alternatively, LPS may remain bound to mCD14 while being internalized, exhibiting the behavior of a classic ligand–receptor complex.
To determine whether mCD14 traffics along with LPS from the plasma membrane to intracellular compartments, we constructed a GPI-anchored fusion protein of CD14 and enhanced green fluorescent protein (EGFP) and used it to follow the location of mCD14 in the astrocytoma cell line U373. The fusion protein was expressed on the cell surface in a fully functional form. Expression of mCD14–EGFP endowed U373 cells with the ability to internalize detectable amounts of fluorescently labeled LPS (BODIPY–LPS). Using confocal microscopy, we observed that BODIPY–LPS presented in a monomeric form colocalized with mCD14 at the cell surface but distributed to intracellular locations without mCD14 as soon as internalization of LPS could be detected. Our observations suggest that monomeric LPS is rapidly transferred out of mCD14 at the plasma membrane and traffics within the cell independently of mCD14. Additional studies indicate that LPS aggregates are trafficked differently from monomers. LPS aggregates are known to be slowly internalized and directed to lysosomes 18, and we find that mCD14 remains associated with LPS aggregates during internalization.
![]()
Materials and Methods
Top
Abstract
Materials and Methods
Results
Discussion
References
Construction of the mCD14–EGFP and mEGFP Chimeras.
pEGFP-N1 (Clontech) encodes EGFP, a bright red–shifted variant of GFP containing the amino acid substitutions phenylaline-64
leucine and serine-65
threonine of GFPmut1 19. An mCD14–EGFP gene fusion was constructed in pEGFP-N1 in two steps. First, a 1.2-kb BamHI fragment coding for the entire CD14 protein minus the last eight COOH-terminal residues was inserted into BamHI-digested pEGFP-N1, yielding pCD14–EGFP. Second, a 116-bp BsrGI–NotI fragment, encoding the 36 COOH-terminal residues of decay accelerating factor (DAF) and a stop codon, was inserted into BsrGI- plus NotI-digested pCD14–EGFP, yielding pCD14–EGFP–GPI. The amino acid sequence of the fusion protein coded by this construct is shown (see Fig. 1 A).
|
The 1.2-kb BamHI fragment encoding most of CD14 was synthesized by PCR using pcDNAI-neo-CD14 as a template 20 and the primers 5'-GAG atg gat cca cca tgg agc gcg cgt cct gc-3' and 5'-GAG ATG GAT CCA GCA CCA GGG TTC CCG A-3'. The 116-bp BsrGI–NotI fragment encoding part of DAF was synthesized by RT-PCR using total RNA from human monocytes as a template and the primers 5'-aat atg tac aat aaa gga agt gga acc ac-3' and 5'-taa agc ggc cgc taa gtc agc aag ccc at-3'. The 134-bp SalI–BamHI fragment was synthesized by RT-PCR using total RNA from human neutrophils as a template and the primers 5'-ACG CGT CGA CGC CGC TGT GTA GGA AAG-3' and 5'-CGC GGA TCC GCA GAG ACG TGC ACC Aat-3'. All syntheses were followed by digestion with the appropriate restriction enzymes and gel purification. Both RT-PCR amplifications were performed using the Gene Amp RNA PCR kit purchased from Perkin-Elmer Corp. The PCR insertions were sequenced to confirm the absence of PCR synthesis errors.
U373 Cell Lines.
U373 cells were grown as monolayers in RPMI (BioWhittaker, Inc.) supplemented with 10% heat-inactivated fetal bovine serum (FBS; BioWhittaker, Inc.), penicillin/streptomycin (100 U/ml and 100 µg/ml, respectively), and 2 mM glutamine. For making stable transfectants, 105 cells from a confluent culture of U373 cells were seeded on a 35-mm cell culture dish and grown to subconfluence for 24–48 h before transfection with either pCD14–EGFP–GPI or pSP–EGFP–GPI. For each dish, 1–2 µg of highly purified expression plasmid was used for transfection with 6 µl lipofectamine (GIBCO BRL) according to the manufacturer's instructions. The DNA–lipofectamine mixture remained on the cells for 6 h at 37°C and was then replaced by RPMI with 10% FBS and 2 mM glutamine without antibiotics. 72 h after transfection, the cells were trypsinized, plated at clonal density, and selected with 0.5 mg/ml geneticin (GIBCO BRL). After 3 wk, surviving cell colonies were visually screened for fluorescence. Several positive clones were identified, isolated using cloning rings, and expanded into cell lines for further analysis. U373–CD14 cells were obtained by selecting clones of U373 cells stably transfected with pcDNAI-neo-CD14 as described elsewhere 20.
sCD14 and LPS.
Recombinant human sCD14 was purified from conditioned medium of Schneider-2 insect cells transfected with cDNA encoding human CD14 as previously described 21. LPS from Salmonella minnesota R595 was purchased from List Biological Labs. The fluoroprobe BODIPY 558/568 (Molecular Probes, Inc.) was conjugated to unlabeled LPS micelles as previously described 22.
LPS–sCD14 and BODIPY–LPS–sCD14 complexes were formed by incubating LPS or BODIPY–LPS (20 µg/ml), respectively, with sCD14 (500 µg/ml) overnight at 37°C in Dulbecco's PBS (BioWhittaker, Inc.) with 0.5% pyrogen-free human serum albumin (Centeon, Armour, and Berring Pharmaceutical Co.). Previous work has shown that under these conditions all of the LPS forms stoichiometric complexes with monomeric sCD14 and that these complexes efficiently stimulate cells and deliver LPS to the plasma membrane 23.
BODIPY–LPS aggregates were prepared by incubating BODIPY–LPS at 1 µg/ml in FBS for 10 min at 37°C. The aggregation state of LPS was verified by monitoring its fluorescence emission at 568 nm before and after the addition of detergent, as described elsewhere 22. Adding 2% SDS to the BODIPY–LPS aggregates led to a 10-fold increase in fluorescence due to the loss of self-quenching as monomers were released from the aggregates. In addition, aggregates observed directly by fluorescence microscopy exhibited a pointillistic pattern of fluorescence, rather than the very diffuse fluorescence seen with BODIPY–LPS–sCD14 complexes.
Confocal Microscopy.
U373 transfectants were cultured for 24–48 h before experiments in RPMI without phenol red (BioWhittaker, Inc.) supplemented with 10% FBS, antibiotics, and 2 mM glutamine on glass chamber slides (Nunc, Inc.) precoated with 0.5% gelatin (Sigma Chemical Co.). The cells were washed twice in HAP buffer (Dulbecco's PBS, 0.05% human serum albumin, and 3 mM D-glucose, containing 0.5 U/ml of aprotinin) and incubated in HAP at 37°C with or without LPS–sCD14, BODIPY–LPS–sCD14, or BODIPY–LPS aggregates. Slides were washed twice with HAP and further incubated at 37°C. At the end of the incubation, the plastic chamber and silicone gasket were removed, and the slide was mounted in HAP for immediate microscopic observation. For removal of cell surface mCD14–EGFP with phosphatidyl inositol phospholipase C (PI-PLC), cells on slides were incubated for 1 h in 20 mM Hepes, pH 7.4, and 150 mM NaCl on ice with 5 U/ml of PI-PLC (Boehringer Mannheim).
When anti-CD14 mAb 26ic or 60b 23 was used, cells were incubated with the antibody at 10 µg/ml in HAP buffer at 4°C for 30 min and washed twice with ice-cold HAP and once with HAP at 37°C just before adding the BODIPY–LPS–sCD14 complexes.
Confocal scanning laser microscopy was performed using a Nikon Optiphot-2 microscope with a x60 objective (NA 1.4) and Bio-Rad MRC 1024 instrumentation with a krypton/argon laser. Unless otherwise noted, each image represents a single Kalman averaged (6–10 scans) optical section collected with a 2–3-mm-diameter iris aperture. Optical sections were collected digitally and analyzed using LaserSharp software (Bio-Rad Labs.). For two-color images, each color was acquired sequentially. This was necessary because EGFP has a broad peak of fluorescence, and some signal bleedthrough was observed in the BODIPY–LPS channel when simultaneous collection was attempted.
Intracellular Fluorescence.
Quenching of cell surface fluorescence by trypan blue was employed to both quantitate and observe the distribution of intracellular mCD14–EGFP and mEGFP. U373 transfectants were grown to confluence in a 96-well culture plate and, after the experiment, the total fluorescence associated with the cells was measured using a Cytofluor 4000 (PE Biosystems) (excitation 485 nm, emission 530 nm). Trypan blue (200 µg/ml, ambient temperature) was added to the wells to quench fluorescence from cell surface EGFP, and the remaining fluorescence from intracellular mCD14–EGFP or mEGFP was immediately measured. Intracellular fluorescence is expressed as a percent of total fluorescence from triplicate samples. Trypan blue was also used to quench cell surface EGFP on U373 transfectants before observing the cells by confocal microscopy. After the experimental manipulation, U373 transfectants cultured on glass chamber slides were washed once and mounted in HAP containing 200 µg/ml trypan blue before immediate observation.
IL-6 Production by U373 Cells.
U373 transfectants grown in 96-well cell culture plates were washed extensively with AIM-V serum–free medium (GIBCO BRL) and incubated as indicated in AIM-V medium containing 0.5 mg/ml human serum albumin. After 16 h at 37°C, the overlying medium was collected from each well and assayed for IL-6 by ELISA as described 24.
SDS-PAGE and Western Blotting.
For each condition, 106 cells were lysed by incubation on ice for 20 min in 300 µl of 100 mM Tris/HCl, pH 8.0, 100 mM NaCl, 2 mM EDTA, 1% Triton X-100, 0.1% SDS, 0.3 U/ml aprotinin, 2 mM PMSF, 3 mM diisopropyl fluorophosphate, 50 µg/ml benzamidine, and 5 µg/ml each of antipain, leupeptin, chymostatin, and pepstatin A. Lysates were centrifuged for 15 min at 12,000 g, and the supernatants were prepared for SDS-PAGE under reducing conditions. SDS-PAGE was run on a 4–20% gradient Tris–glycine gel (Novex). Proteins were electrotransferred to nitrocellulose membranes and detected with either an anti-EGFP rabbit pAb (Clontech) or an anti-CD14 pAb 25. Horseradish peroxidase–conjugated goat anti–rabbit IgG was used as the secondary antibody, and the enzymatic reaction was detected with an ECL kit (Amersham Corp.). Purified rEGFP was obtained from Clontech.
| Results |
|---|
|
|
|---|
The two gene fusion products were transfected into the U373 astrocytoma cell line, which does not express mCD14. Stable transfectants for mCD14–EGFP and mEGFP were designated U373–CD14–EGFP and U373–EGFP, respectively. One clone of U373–CD14–EGFP was used for the results presented, but a second clone gave identical results.
Expression of mCD14–EGFP as an intact polypeptide in U373–CD14–EGFP was tested in Western blots of cell lysates run in parallel with rsCD14 and EGFP. Antibodies against either CD14 or EGFP recognized the appropriate control protein and the same single band at 80 kD in U373–CD14–EGFP (Fig. 2). The band corresponded to a protein of the expected mass for mCD14–EGFP and was not present in cell lysates of untransfected U373. Thus, mCD14–EGFP was expressed in U373 cells as an intact polypeptide, and we can be confident that by observing EGFP fluorescence we are also observing the location of mCD14.
|
|
EGFP-tagged mCD14 Enhances Responses of U373 Cells to LPS.
U373 astrocytoma cells do not respond to LPS alone, but when LPS is added in the presence of sCD14, they produce IL-6 26. Transfection of U373 cells with mCD14 allows responses to LPS in the absence of sCD14. More importantly, it greatly increases the sensitivity of these cells to LPS–sCD14 complexes and allows more rapid responses to LPS–sCD14. This is consistent with observations that mCD14 on neutrophils and monocytes is necessary for responses to LPS in the absence of sCD14 and greatly increases the sensitivity of their responses to LPS–sCD14 complexes 29.
To show that the mCD14–EGFP chimera was functional, we measured secretion of IL-6 by U373–CD14–EGFP and U373–EGFP cells in response to either LPS or LPS–sCD14 complexes. The U373–EGFP cells did not respond to LPS alone up to 100 ng/ml (Fig. 4 A). In contrast, expression of mCD14–EGFP in U373 cells led to IL-6 production in response to concentrations of LPS of 1 ng/ml or higher. Similarly, U373–CD14–EGFP cells responded to concentrations of LPS–sCD14
100-fold lower than those required to elicit the same response in U373–EGFP cells (Fig. 4 A). The enhancement of sensitivity by mCD14–EGFP was quantitatively similar to that previously observed with mCD14. Thus, the presence of EGFP does not affect the function of mCD14–EGFP on cells.
|
Taken together, these results suggest that mCD14–EGFP was able to bind LPS and mediate cellular responses to it. All of the properties exhibited by U373–CD14–EGFP are the same as those of mCD14 expressed in U373, indicating that mCD14 expressed as a chimera with EGFP was still a functional entity. These results further suggest that the distribution and trafficking pattern of mCD14–EGFP in U373 would reflect that of a fully functional protein.
LPS Binds to U373–CD14–EGFP and Colocalizes with mCD14 on the Cell Surface.
The association of LPS with mCD14–EGFP was confirmed by confocal microscopy. BODIPY–LPS in the form of monomeric complexes with sCD14 was incubated with U373–CD14–EGFP for 2–3 min at 37°C before washing and observation. Fluorescence from BODIPY–LPS was seen associated with the plasma membrane of U373–CD14–EGFP (Fig. 5 A, no Ab, red panel), indicating that it was successfully transferred from sCD14. There was colocalization of BODIPY–LPS with mCD14–EGFP on the cell surface, as demonstrated by the overlap in fluorescence signals (Fig. 5 A, no Ab, merge panel). The same cell surface distribution of BODIPY–LPS was observed with U373 transfectants expressing mCD14 without EGFP attached (Fig. 5 B, panel d). In contrast, U373–EGFP cells incubated briefly with BODIPY–LPS–sCD14 complexes did not have detectable BODIPY–LPS fluorescence associated with their cell surfaces (Fig. 5 B, panels a and b).
|
When Presented in a Monomeric Form, LPS Is Internalized Separately from mCD14.
To determine whether LPS remained bound to mCD14 after internalization, we observed the trafficking of mCD14–EGFP and BODIPY–LPS simultaneously in live cells. U373–CD14–EGFP cells were incubated with BODIPY–LPS–sCD14 complexes for 2–3 min at 37°C, the complexes were removed by washing, and the cells were incubated further at 37°C before observation. Particular attention was devoted to observations made 5–10 min after the incubation began. At the earliest time points, BODIPY–LPS was clearly visible in small intracellular vesicles (Fig. 6, 10 min, red panel). These vesicles were visible at times as early as 5 min (data not shown). However, the vesicles containing BODIPY–LPS did not contain mCD14–EGFP, as evidenced by the lack of overlap in fluorescent signals (Fig. 6, 10 min, merge panel). This indicates that in the brief time required for LPS to reach a vesicular location, LPS had separated from mCD14.
|
The kinetics of BODIPY–LPS internalization in U373–CD14–EGFP were identical to those in U373 expressing mCD14 without EGFP (data not shown). Furthermore, the distribution of intracellular BODIPY–LPS in vesicles and their subcellular localization was the same in both cell types (data not shown). This indicates that the presence of EGFP on mCD14 did not disturb the normal trafficking pattern of LPS in U373 cells.
Intracellular CD14 Is Exocytosed in Response to LPS.
Although there was no apparent change in the distribution of mCD14–EGFP in response to LPS in the colocalization studies, the bright cell surface fluorescence prevented observation of any changes in the distribution of intracellular mCD14–EGFP. To better observe the distribution of intracellular mCD14–EGFP, we quenched the cell surface fluorescence on U373–CD14–EGFP cells with trypan blue (Fig. 7A and Fig. B). In addition to the bright fluorescence emanating from the Golgi apparatus area, numerous fluorescent vesicles of
50–100-nm average diameter were distributed throughout the cytoplasm. The vesicles were particularly evident near the basal aspects of the cells (Fig. 7 B). A similar intracellular localization of mEGFP in the Golgi complex and cytoplasmic vesicles was also observed (data not shown). Thus, the vesicular compartment may represent either a component of the secretory pathway en route to the cell surface or a recycling compartment for GPI-anchored proteins.
|
Exocytosis of the mCD14-containing vesicles was confirmed by quantitative measurements of the time course. U373–CD14–EGFP cells were grown in 96-well tissue culture plates, and both total and intracellular fluorescence was measured before and at various times after exposure to LPS–sCD14 complexes (see Materials and Methods). Stimulation with LPS did not induce any change in total fluorescence associated with the cells (data not shown) but did induce a rapid decrease in intracellular mCD14–EGFP (Fig. 8). A decrease of
20% in the intracellular fluorescence was observed after a 15-min incubation of U373–CD14–EGFP cells with LPS–sCD14 complexes. A similar decrease in intracellular fluorescence associated with U373–EGFP cells was observed in response to LPS–sCD14 complexes (Fig. 8), indicating that the compartments released contained GPI-anchored proteins in addition to mCD14–EGFP.
|
To determine whether mCD14 traffics with LPS aggregates during internalization, we incubated U373–CD14–EGFP with BODIPY–LPS aggregates at concentrations between 40 and 100 ng/ml and followed both BODIPY–LPS and mCD14–EGFP fluorescence by confocal microscopy. After incubation for 5–10 min at 37°C with BODIPY–LPS aggregates, the cells were washed and incubated further at 37°C. The aggregates bound to the cell surface and colocalized with mCD14–EGFP (Fig. 9). At least 15 min at 37°C was required to detect BODIPY–LPS in intracellular vesicles, suggesting that internalization of LPS aggregates was somewhat slower than internalization of LPS monomers in U373–CD14–EGFP. The mCD14–EGFP colocalized with BODIPY–LPS in intracellular vesicles detected at the earliest times, although not all of the vesicles that contained BODIPY–LPS also contained mCD14–EGFP. These results suggest that, in contrast with LPS monomers, LPS aggregates can remain bound to mCD14 during internalization. This supports the idea that there is more than one pathway for internalization of LPS.
|
| Discussion |
|---|
|
|
|---|
Using this method, we observed that mCD14 was not only expressed on the cell surface but was also present intracellularly both in the perinuclear area and in small vesicles near the basal aspect of the cells. These vesicles might represent compartments in which mCD14, and perhaps other GPI-anchored proteins, traffic from the Golgi apparatus to the plasma membrane. They may also represent a recycling compartment for GPI-linked proteins that are internalized from the plasma membrane and then returned to it 31. Most of these vesicles were exocytosed when U373–CD14–EGFP cells were exposed to LPS–sCD14 complexes, indicating that they are capable of fusion with the plasma membrane.
The rapid exocytosis of the vesicles containing mCD14–EGFP upon stimulation of U373–CD14–EGFP cells with LPS was reminiscent of the exocytosis of secretory vesicles containing mCD14 and other GPI-anchored proteins upon stimulation of neutrophils with an agonist 25. Secretory vesicles are thought to be an endocytic compartment, as they also contain the serum proteins albumin and tetranectin 3233. In response to formyl peptide, secretory vesicles are brought rapidly to the neutrophil surface, augmenting the expression of GPI-anchored proteins on the plasma membrane 25. Additional studies will be required to determine whether any of the mCD14-containing vesicles in U373–CD14–EGFP cells represent a recycling compartment for GPI-anchored proteins similar to the secretory vesicles of neutrophils.
Expression of mCD14–EGFP on the plasma membrane enabled uptake of BODIPY–LPS (Fig. 5 and Fig. 6) and cellular responses to LPS (Fig. 4 A). CD14 binds LPS 34 and, not surprisingly, added LPS was found to colocalize with plasma membrane mCD14–EGFP (Fig. 5 and Fig. 6). After association with the membrane, monomeric LPS is known to be rapidly internalized 1314. Here we show that when LPS was internalized, it moved into intracellular vesicles that did not contain mCD14. Thus, we have demonstrated in living cells that LPS, once it is bound by mCD14 on the cell surface, is internalized without being accompanied by its receptor. Together with our previous observations that each mCD14 on the surfaces of human monocytes enables the uptake of 15 LPS molecules in 30 min 3 and that this uptake depends on an additional cell surface protein 3, these observations support a model for LPS trafficking that involves transfer of LPS from mCD14 to another cell surface protein or to the lipid bilayer of the plasma membrane.
In addition to our studies with monomeric LPS, we have also observed the trafficking of LPS aggregates. Aggregated LPS may engage multiple copies of mCD14 on the cell surface at the same time, and it may be more difficult for mCD14 to transfer LPS from aggregates to the plasma membrane. Using the mCD14–EGFP chimera, we observed that mCD14 was internalized with aggregated LPS in U373 cells. This behavior is opposite to that of LPS monomers. It is, however, consistent with a variety of other studies documenting different fates of monomeric and aggregated LPS. After internalization, primarily through noncoated structures 35, LPS aggregates move over the course of several hours into a compartment that is likely to be lysosomal in nature. There, acyloxyacyl hydrolase deacylates and thus detoxifies LPS 18. Internalization of aggregates can be disassociated from signaling 2729 and thus appears more relevant to the detoxification and clearance of LPS rather than signaling.
Several observations indicate a close correlation between signaling and LPS transit to the Golgi complex. For example, inactive structural analogues of LPS are not transported to the Golgi complex 15, and cells from Lpsd mice, which exhibit a defect in LPS signaling, fail to transport LPS to the Golgi complex 14. Recent work has shown that Lpsd mice are defective in Toll-like receptor (TLR)4, a member of the IL-1 receptor family 36. In this regard, it is interesting to note that the ligated IL-1 receptor type I (IL-1RI) may require trafficking to an intracellular compartment to generate signals 37. A thymocyte cell line has been identified that is defective in its responses to IL-1 and also does not internalize IL-1RI. The defect can be overcome by intracellular delivery of IL-1 38 or by transfection with IL-1R accessory protein (IL-1RAcP), which restores both IL-1RI internalization 39 and IL-1 responses 39. Interaction of IL-1 with IL-1RI and IL-1RAcP triggers a cascade of signaling events, including activation of the stress-activated, mitogen-activated protein (MAP) kinase pathways and transcription factor NF-
B. Of interest in this regard is that TLR4 shares homology in its cytoplasmic domain with the IL-1R family 40, suggesting the possibility that it may also share similar directions of intracellular trafficking. Whether TLR4 colocalizes with LPS before or after transport to the Golgi complex, however, will have to await further studies.
| Acknowledgments |
|---|
Submitted: 12 February 1999
Revised: 11 June 1999
Accepted: 22 June 1999
A preliminary version of this work was presented at the Fifth Conference of the International Endotoxin Society, Santa Fe, NM, September 12–15, 1998.
Le Grand, C.B., N. Lamping, T. Sugiyama, S.D. Wright, and R. Thieringer, manuscript submitted for publication.
| References |
|---|
|
|
|---|
Wright S.D.. CD14 and innate recognition of bacteria, J. Immunol., 155, 1995, 6–8.[Medline]
Hailman E., Vasselon T., Kelley M., Busse L.A., Hu M.C.-T., Lichenstein H.S., Detmers P.A. & Wright S.D.. Stimulation of macrophages and neutrophils by complexes of lipopolysaccharide and soluble CD14, J. Immunol., 156, 1996, 4384–4390.[Abstract]
Vasselon T., Pironkova R. & Detmers P.A.. Sensitive responses of leukocytes to lipopolysaccharide require a protein distinct from CD14 at the cell surface, J. Immunol., 159, 1997, 4498–4505.[Abstract]
Wright S.D., Ramos R.A., Tobias P.S., Ulevitch R.J. & Mathison J.C.. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein, Science., 249, 1990, 1431–1433.
Wright S.D., Ramos R.A., Hermanowski-Vosatka A., Rockwell P. & Detmers P.A.. Activation of the adhesive capacity of CR3 on neutrophils by endotoxindependence on lipopolysaccharide binding protein and CD14, J. Exp. Med., 173, 1991, 1281–1286.
Sundan A., Gullstein-Jahr T., Otterlei M., Ryan L., Bazil V., Wright S.D. & Espevik T.. Soluble CD14 from urine copurifies with a potent inducer of cytokines, Eur. J. Immunol., 24, 1994, 1779–1784.[Medline]
Golenbock D.T., Bach R.R., Lichenstein H., Juan T.S.-C., Tadavarthy A. & Moldow C.F.. Soluble CD14 promotes LPS activation of CD14-deficient PNH monocytes and endothelial cells, J. Lab. Clin. Med., 125, 1995, 662–671.[Medline]
Duchow J., Marchant A., Crusiaux A., Husson C., Alonso-Vega C., De Groote D., Neve P. & Goldman M.. Impaired phagocyte responses to lipopolysaccharide in paroxysmal nocturnal hemoglobinuria, Infect. Immun., 61, 1993, 4280–4285.
Haziot A., Ferrero E., Kontgen F., Hijiya N., Yamamoto S., Silver J., Stewart C.L. & Goyert S.M.. Resistance to endotoxin shock and reduced dissemination of gram-negative bacteria in CD14-deficient mice, Immunity., 4, 1996, 407–414.[Medline]
Golenbock D.T., Liu Y., Millham F.H., Freeman M.W. & Zoeller R.A.. Surface expression of human CD14 in Chinese hamster ovary fibroblasts imparts macrophage-like responsiveness to bacterial endotoxin, J. Biol. Chem., 268, 1993, 22055–22059.
Lee J.-D., Kato K., Tobias P.S., Kirkland T.N. & Ulevitch R.J.. Transfection of CD14 into 70Z/3 cells dramatically enhances the sensitivity to complexes of lipopolysaccharide (LPS) and LPS binding protein, J. Exp. Med., 175, 1992, 1697–1703.
Wang P.Y., Kitchens R.L. & Munford R.S.. Phosphatidylinositides bind to plasma membrane CD14 and can prevent monocyte activation by bacterial lipopolysaccharide, J. Biol. Chem., 273, 1998, 24309–24313.
Detmers P.A., Thieblemont N., Vasselon T., Pironkova R., Miller D.S. & Wright S.D.. Potential role of membrane internalization and vesicle fusion in adhesion of neutrophils in response to lipopolysaccharide and TNF, J. Immunol., 157, 1996, 5589–5596.[Abstract]
Thieblemont N. & Wright S.D.. Mice genetically hyporesponsive to lipopolysaccharide (LPS) exhibit a defect in endocytic uptake of LPS and ceramide, J. Exp. Med., 185, 1997, 2095–2100.
Thieblemont N., Thieringer R. & Wright S.D.. Innate immune recognition of bacterial lipopolysaccharidedependence on interactions with membrane lipids and endocytic movement, Immunity., 8, 1998, 771–777.[Medline]
Wurfel M.M., Hailman E. & Wright S.D.. Soluble CD14 acts as a shuttle in the neutralization of LPS by LPS-binding protein and reconstituted high-density lipoprotein, J. Exp. Med., 181, 1995, 1743–1754.
Wurfel M.M. & Wright S.D.. Lipopolysaccharide-binding protein and soluble CD14 transfer lipopolysaccharide to phospholipid bilayerspreferential interaction with particular classes of lipid, J. Immunol., 158, 1997, 3925–3934.[Abstract]
Luchi M. & Munford R.S.. Binding, internalization, and deacylation of bacterial lipopolysaccharide by human neutrophils, J. Immunol., 151, 1993, 959–969.[Abstract]
Cormack B.P., Valdivia R.H. & Falkow S.. FACS-optimized mutants of the green fluorescent protein (GFP), Gene., 173, 1996, 33–38.[Medline]
LeGrand C.B. & Thieringer R.. CD14-dependent induction of protein tyrosine phosphorylation by lipopolysaccharide in murine B-lymphoma cells, Biochim. Biophys. Acta., 1223, 1994, 36–46.[Medline]
Detmers P.A., Zhou D., Polizzi E., Thieringer R., Hanlon W.A., Vaidya S. & Bansal V.. Role of stress-activated mitogen-activated protein kinase (p38) in beta 2-integrin-dependent neutrophil adhesion and the adhesion-dependent oxidative burst, J. Immunol., 161, 1998, 1921–1929.
Yu B. & Wright S.D.. Catalytic properties of lipopolysaccharide (LPS) binding protein (LBP). Transfer of LPS to soluble CD14, J. Biol. Chem., 271, 1996, 4100–4105.
Todd R.F., Van A.A., Schlossman S.F. & Terhorst C.. Structural analysis of differentiation antigens Mo1 and Mo2 on human monocytes, Hybridoma., 1, 1982, 329–337.[Medline]
Kusunoki T., Hailman E., Juan T.S.-C., Lichenstein H.S. & Wright S.D.. Molecules from Staphylococcus aureus that bind CD14 and stimulate innate immune responses, J. Exp. Med., 182, 1995, 1673–1682.
Detmers P.A., Zhou D., Powell D., Lichenstein H., Kelley M. & Pironkova R.. Endotoxin receptors (CD14) are found with CD16 (Fc
RIII) in an intracellular compartment of neutrophils that contains alkaline phosphatase, J. Immunol., 155, 1995, 2085–2095.[Abstract]
Frey E.A., Miller D.S., Jahr T.G., Sundan A., Bazil V., Espevik T., Finlay B.B. & Wright S.D.. Soluble CD14 participates in the response of cells to lipopolysaccharide, J. Exp. Med., 176, 1992, 1665–1671.
Gegner J.A., Ulevitch R.J. & Tobias P.S.. Lipopolysaccharide (LPS) signal transduction and clearance. Dual roles for LPS binding protein and membrane CD14, J. Biol. Chem., 270, 1995, 5320–5325.
Poussin C., Foti M., Carpentier J.L. & Pugin J.. CD14-dependent endotoxin internalization via a macropinocytic pathway, J. Biol. Chem., 273, 1998, 20285–20291.
Kitchens R.L. & Munford R.S.. CD14-dependent internalization of bacterial lipopolysaccharide (LPS) is strongly influenced by LPS aggregation but not by cellular responses to LPS, J. Immunol., 160, 1998, 1920–1928.
Mayor S., Rothberg K.G. & Maxfield F.R.. Sequestration of GPI-anchored proteins in caveolae triggered by cross-linking, Science., 264, 1994, 1948–1951.
Maxfield F.R. & Mayor S.. Cell surface dynamics of GPI-anchored proteins, Adv. Exp. Med. Biol., 419, 1997, 355–364.[Medline]
Borregaard N., Christensen L., Bejerrum O.W., Birgens H.S. & Clemmensen I.. Identification of a highly mobilizable subset of human neutrophil intracellular vesicles that contains tetranectin and latent alkaline phosphatase, J. Clin. Invest., 85, 1990, 408–416.[Medline]
Borregaard N., Kjeldsen L., Rygaard K., Bastholm L., Nielsen M.H., Sengelov H., Bjerrum O.W. & Johnsen A.H.. Stimulus-dependent secretion of plasma proteins from human neutrophils, J. Clin. Invest., 90, 1992, 86–96.[Medline]
Hailman E., Lichenstein H.S., Wurfel M.M., Miller D.S., Johnson D.A., Kelley M., Busse L.A., Zukowski M.M. & Wright S.D.. Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14, J. Exp. Med., 179, 1994, 269–277.
Kitchens R.L., Wang P. & Munford R.S.. Bacterial lipopolysaccharide can enter monocytes via two CD14-dependent pathways, J. Immunol., 161, 1998, 5534–5545.
Poltorak A., He X., Smirnova I., Liu M.Y., Huffel C.V., Du X., Birdwell D., Alejos E., Silva M. & Galanos C.. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr micemutations in tlr4 gene, Science., 282, 1998, 2085–2088.
Hofmeister R., Wiegmann K., Korherr C., Bernardo K., Kronke M. & Falk W.. Activation of acid sphingomyelinase by interleukin-1 (IL-1) requires the IL-1 receptor accessory protein, J. Biol. Chem., 272, 1997, 27730–27736.
Hofmeister R., Mannel D.N. & Falk W.. Evidence for an intracellular activation loop in the IL-1 system, J. Inflamm., 47, 1995, 151–163.[Medline]
Wesche H., Korherr C., Kracht M., Falk W., Resch K. & Martin M.U.. The interleukin-1 receptor accessory protein (IL-1RAcP) is essential for IL-1-induced activation of interleukin-1 receptor-associated kinase (IRAK) and stress-activated protein kinases (SAP kinases), J. Biol. Chem., 272, 1997, 7727–7731.
Rock F.L., Hardiman G., Timans J.C., Kastelein R.A. & Bazan J.F.. A family of human receptors structurally related to Drosophila Toll, Proc. Natl. Acad. Sci. USA., 95, 1998, 588–593.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| TABLE OF CONTENTS |
|